O

Option Care Health

Largest independent home infusion therapy provider

Specialty Sales Representative

Full-TimeUpdated on 10/23/2026
$96.9k - $161.6k
Junior, Mid
Bachelor's, Associate's
Los Angeles, CA, USA+8 moreMore locations: Thousand Oaks, CA, USA | Lancaster, CA, USA | Oxnard, CA, USA | Palmdale, CA, USA | Bakersfield, CA, USA | Ventura, CA, USA | San Luis Obispo, CA, USA | Santa Barbara, CA, USA
In PersonTravel within the territory is required 90% of the time.
Sales & Account ManagementField Sales

About the job

Requirements
  • A high school diploma or equivalent is required.
  • Have 2–5 years of experience in business-to-business or healthcare sales, with a proven ability to generate referrals and grow revenue.
  • Demonstrate success in the infusion center, specialty pharmacy, or related healthcare market.
  • Have experience using a customer relationship management (CRM) system to track sales activity and customer engagement.
  • Have a valid driver’s license and ability to travel within the territory 90% of the time.
  • Have outstanding verbal and written communication skills.
  • Be able to translate company strategy into persuasive messaging tailored to the provider audience.
  • Have strong interpersonal skills to build rapport and maintain long-term business relationships.
  • Be self-motivated and goal-oriented, with a demonstrated history of meeting or exceeding sales targets.
  • Have excellent organizational skills and the ability to manage multiple priorities in a fast-paced environment.
  • Have a customer-focused mindset with strong problem-solving and learning agility.
Responsibilities
  • Identify, establish, and maintain relationships with targeted physician offices and referral sources to increase patient referrals to Option Care Health.
  • Deliver persuasive and strategic sales presentations to physicians, office staff, and other key stakeholders.
  • Partner with clinical and administrative staff, such as biologics coordinators, to promote Option Care Health’s infusion services.
  • Execute daily face-to-face sales calls while maintaining activity levels outlined in the sales plan.
  • Document sales activities and customer interactions in the company’s CRM system in a timely and accurate manner.
  • Collaborate cross-functionally with internal teams to ensure superior customer service and support patient onboarding.
  • Travel within the territory promoting Option Care Health’s infusion capabilities and value messages across specialties in physician offices.
  • In markets with Ambulatory Infusion Clinics, drive demand to fill the clinics.
  • Build and execute in-person call plans, fully utilize the CRM, and apply a disciplined approach to building and growing the territory.
  • Partner with operations teammates to ensure updates, solutions, and high customer satisfaction levels are provided to referral sources.
  • Adapt as new therapies and call points are added.
Desired Qualifications
  • An associate’s or bachelor’s degree in healthcare, business, or a related field is preferred.
  • Prior experience in IV infusion therapy, specialty pharmacy, or biologic drug promotion is highly desirable.

About the company

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bannockburn, Illinois

Founded

1979

Get referred to Option Care Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 29, 2026 Q2 revenue reached $1.44 billion, while acute therapy and IG Neuro strengthened.
  • Management stabilized CID patient census in Q2 2026 and kept full-year revenue guidance unchanged.
  • The company repurchased $150 million in Q2 2026, signaling confidence and shareholder-return capacity.

What critics are saying

  • August 2026 guidance still bakes in a 600-basis-point CID revenue headwind and $55 million gross profit hit.
  • July 29, 2026 Q2 buyback of $150 million masks weak top-line momentum and analyst skepticism.
  • Biosimilar erosion and payer reverification pressure can permanently shrink chronic volumes if retention stays broken.

What makes Option Care Health unique

  • Option Care Health leads U.S. independent home and alternate-site infusion, with nationwide clinician density.
  • Its payer, biopharma, and prescriber relationships create switching costs across chronic and acute therapies.
  • August 27, 2026 guidance shows durable cash generation, with at least $320 million operating cash flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Time Off
  • Bonding Time Off
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Health Savings Account/Flexible Spending Account
  • Flexible Spending Accounts
  • Tuition Reimbursement
  • Family Support
  • Mental Health Support

Company News

AD HOC NEWS
Oct 15th, 2026
McKesson commits $1.4B for 49% stake in Option Care at $5.8B valuation

McKesson will invest $1.4 billion for a 49% minority stake in Option Care Health, under an agreement announced on October 6, 2026. The deal values Option Care at an enterprise value of $5.8 billion. Clayton, Dubilier & Rice will hold about 51%. Option Care will stay separately managed, while McKesson keeps a framework to acquire the remaining interest later, subject to conditions and regulatory approvals. In its first fiscal 2027 quarter, McKesson reported revenue of $105.38 billion, up 7.7% year on year, and adjusted earnings per share of $9.93. It will report second-quarter results on November 4, 2026.

Yahoo Finance
Oct 6th, 2026
McKesson and Clayton Dubilier & Rice near $5B deal to acquire Option Care Health

Option Care Health shares jumped 33.2% in pre-market trading after the Financial Times reported McKesson and Clayton Dubilier & Rice are nearing a transaction valued at over $5 billion to acquire the alternate site health provider. According to the report, the deal would involve the two firms partnering to buy the infusion services provider, which they view as undervalued. Large-scale buyout discussions typically drive market optimism as investors anticipate acquisition premiums. The move is significant for Option Care Health, whose shares have experienced 13 movements greater than 5% over the past year. At $31.03 per share, the stock is trading 15.2% below its 52-week high but remains down 3.8% year-to-date.

Central Charts
Oct 6th, 2026
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health

CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have

Yahoo Finance
Jul 29th, 2026
Option Care Health Q2 beats expectations with $1.4B revenue, narrows full-year guidance

Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.

Yahoo Finance
Jul 29th, 2026
Option Care Health reports $1.44B Q2 revenue, up 1.9%, and raises $150M share buyback

Option Care Health, the largest independent provider of home and alternate site infusion services in the US, reported second quarter 2026 results. Net revenue reached $1.44 billion, up 1.9% year-over-year. The company posted net income of $53.9 million, up 6.7%, with diluted earnings per share of $0.35, up 12.9%. Adjusted EBITDA grew 3.0% to $117.5 million. The company repurchased $150 million of outstanding shares during the quarter. For full year 2026, Option Care Health expects net revenue between $5.68 billion and $5.78 billion, with adjusted diluted earnings per share of $1.85 to $1.92. The company forecasts adjusted EBITDA of $480 million to $495 million and operating cash flow of at least $320 million.